Skip to content
Back to SEPN

Septerna, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
40
Purchases
0
Sales
40
Purchase value
$0.00
Sale value
$49.16M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Jeffrey FinerDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Nov 16, 2026Period of report Nov 12, 20260001193125-26-464072
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 12, 2026
Common StockF2F35,600$42.0888$235.70K846,809Direct
SaleNov 12, 2026
Common StockF2F45,300$43.0959$228.41K841,509Direct
SaleNov 12, 2026
Common StockF2F52,800$44.2261$123.83K838,709Direct
SaleNov 12, 2026
Common StockF2F62,823$45.2751$127.81K835,886Direct
SaleNov 12, 2026
Common StockF2F71,977$46.1631$91.26K833,909Direct
Filing footnotes · 8
  1. F1Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan ("ESPP") on October 31, 2025 and 3,501 shares acquired under the ESPP on April 30, 2026 in transactions that were exempt under Rule 16b-3(c).
  2. F2This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 11, 2026.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.68 to $42.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.68 to $43.48. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. F5The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.69 to $44.63. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  6. F6The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.85 to $45.83. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  7. F7The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.86 to $46.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  8. F81/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Alan EzekowitzDirector
4Rule 10b5-1 plan disclosed
Filed Nov 13, 2026Period of report Nov 11, 20260001193125-26-461248
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 11, 2026
Common StockF1F26,939$46.005$319.23K110,481Direct
SaleNov 11, 2026
Common StockF1F313,201$47.0116$620.60K97,280Direct
SaleNov 11, 2026
Common StockF1F422,865$47.7799$1.09M74,415Direct
SaleNov 11, 2026
Common StockF1F531,572$48.7002$1.54M42,843Direct
SaleNov 11, 2026
Common StockF1F64,175$49.6465$207.27K38,668Direct
SaleNov 11, 2026
Common StockF1F72,013$50.897$102.46K36,655Direct
SaleNov 11, 2026
Common StockF11,055$51.90$54.75K35,600Direct
Filing footnotes · 7
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 13, 2026.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.36 to $46.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.37 to $47.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.37 to $48.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. F5The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.37 to $49.33. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  6. F6The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.38 to $50.31. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  7. F7The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.47 to $51.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open on SEC EDGAR
Elizabeth BhattPresident and COO
4Rule 10b5-1 plan disclosed
Filed Oct 19, 2026Period of report Oct 15, 20260001193125-26-425485
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 15, 2026
Common StockF1F21,094$36.8715$40.34K177,115Direct
SaleOct 15, 2026
Common StockF1F32,906$37.6142$109.31K174,209Direct
Filing footnotes · 4
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 20, 2025.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.24 to $37.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.31 to $38.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F41/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 28, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Daniel D. LongSVP, Drug Discovery
4Rule 10b5-1 plan disclosed
Filed Sep 3, 2026Period of report Sep 1, 20260001193125-26-382267
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 1, 2026
Common StockF1F23,333$37.8271$126.08K96,412Direct
Filing footnotes · 3
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.34 to $38.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F31/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Peter KolchinskyDirector · 10% owner
Capital Healthcare Fund LP RADirector · 10% owner
L.P. RA Capital ManagementDirector · 10% owner
L.P. RA Capital Nexus Fund IIIDirector
Rajeev M. ShahDirector · 10% owner
4
Filed Aug 14, 2026Period of report Aug 12, 20260001231919-26-000938
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 12, 2026
Common StockF1F2746,500$42.50$31.73M4,777,415IndirectSee footnotes
SaleAug 12, 2026
Common StockF1F3746,500$42.50$31.73M725,443IndirectSee footnotes
Filing footnotes · 3
  1. F1RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  2. F2Held directly by the Fund.
  3. F3Held directly by the Nexus Fund III.
Open on SEC EDGAR
Third Rock Ventures GP VI, L.P.10% owner
Third Rock Ventures GP V, LP10% owner
Third Rock Ventures VI, L.P.10% owner
Third Rock Ventures V, L.P.10% owner
TRV GP VI, LLC10% owner
TRV GP V, LLC10% owner
4Rule 10b5-1 plan disclosed
Filed Aug 14, 2026Period of report Aug 12, 20260001193125-26-352692
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 12, 2026
Common StockF1F2F3147,059$50.27$7.39M6,068,532Direct
SaleAug 12, 2026
Common StockF1F4F3141$51.08$7.20K6,068,391Direct
Filing footnotes · 5
  1. F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 26, 2026, previously adopted by the Reporting Person.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.05 to $50.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
  3. F3These shares are directly held by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
  4. F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).
  5. F5The shares are held directly by Third Rock Ventures VI, L.P. ("TRV VI"). The general partner of TRV VI is Third Rock Ventures GP VI, L.P. ("TRV GP VI"). The general partner of TRV GP VI is TRV GP VI, LLC ("TRV GP VI LLC"). Each of TRV GP VI, and TRV GP VI LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between any TRV V related parties and any TRV VI related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.
Open on SEC EDGAR
Elizabeth BhattPresident and COO
4Rule 10b5-1 plan disclosed
Filed Aug 13, 2026Period of report Aug 11, 20260001193125-26-349810
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 11, 2026
Common StockF125,000$44.00$1.10M174,209Direct
Filing footnotes · 3
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 20, 2025.
  2. F21/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 28, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
  3. F31/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Daniel D. LongSVP, Drug Discovery
4Rule 10b5-1 plan disclosed
Filed Aug 5, 2026Period of report Aug 3, 20260001193125-26-335820
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 3, 2026
Common StockF1F21,000$33.9756$33.98K98,746Direct
SaleAug 3, 2026
Common StockF1F32,334$34.6805$80.94K96,412Direct
Filing footnotes · 5
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.39 to $34.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.43 to $35.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F41/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
  5. F51/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Elizabeth BhattPresident and COO
4Rule 10b5-1 plan disclosed
Filed Jul 17, 2026Period of report Jul 15, 20260001193125-26-308073
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 15, 2026
Common StockF1F24,000$33.9935$135.97K174,209Direct
Filing footnotes · 3
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 20, 2025.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.49 to $34.24. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F31/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 28, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Daniel D. LongSVP, Drug Discovery
4Rule 10b5-1 plan disclosed
Filed Jul 2, 2026Period of report Jul 1, 20260001193125-26-295106
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 1, 2026
Common StockF1F22,100$34.0964$71.60K97,645Direct
SaleJul 1, 2026
Common StockF1F31,233$34.8141$42.93K96,412Direct
Filing footnotes · 4
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.49 to $34.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.52 to $35.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F41/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Samira ShaikhlyChief People Officer
4Rule 10b5-1 plan disclosed
Filed Jun 30, 2026Period of report Jun 29, 20260001193125-26-291059
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 29, 2026
Common StockF12,178$35.18$76.62K793Direct
Filing footnotes · 2
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 31, 2025.
  2. F21/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 28, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Daniel D. LongSVP, Drug Discovery
4Rule 10b5-1 plan disclosed
Filed Jun 24, 2026Period of report Jun 22, 20260001193125-26-281461
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 22, 2026
Common StockF2F38,000$35.1001$280.80K103,412Direct
SaleJun 22, 2026
Common StockF2F47,000$35.9687$251.78K96,412Direct
Filing footnotes · 6
  1. F1Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on April 30, 2026 in a transaction that was exempt under Rule 16b-3(c).
  2. F2This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 20, 2026.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.70 to $35.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.71 to $36.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. F51/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
  6. F61/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Samira ShaikhlyChief People Officer
4Rule 10b5-1 plan disclosed
Filed Jun 16, 2026Period of report Jun 12, 20260001193125-26-273126
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 12, 2026
Common StockF1F26,250$35.0759$219.22K793Direct
Filing footnotes · 3
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 31, 2025.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.00 to $35.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F31/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Samira ShaikhlyChief People Officer
4Rule 10b5-1 plan disclosed
Filed Jun 3, 2026Period of report Jun 1, 20260001193125-26-255997
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 1, 2026
Common StockF1F21,700$27.7831$47.23K5,028Direct
SaleJun 1, 2026
Common StockF1F31,346$28.7928$38.76K3,682Direct
SaleJun 1, 2026
Common StockF1F42,889$29.6629$85.70K793Direct
Filing footnotes · 6
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 31, 2025.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.24 to $28.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.25 to $29.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.29 to $30.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. F525% of the shares underlying this option vested on February 1, 2024, with the remainder vesting in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service the Issuer on each such date.
  6. F61/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Samira ShaikhlyChief People Officer
4Rule 10b5-1 plan disclosed
Filed May 28, 2026Period of report May 26, 20260001193125-26-245713
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 26, 2026
Common StockF1F211,798$30.0607$354.66K793Direct
Filing footnotes · 3
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 31, 2025.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.24. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F31/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 28, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Elizabeth BhattPresident and COO
4Rule 10b5-1 plan disclosed
Filed Apr 17, 2026Period of report Apr 15, 20260001193125-26-161987
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 15, 2026
Common StockF1F22,573$23.7558$61.12K175,636Direct
SaleApr 15, 2026
Common StockF1F31,101$25.2394$27.79K174,535Direct
SaleApr 15, 2026
Common StockF1F4326$25.8623$8.43K174,209Direct
Filing footnotes · 5
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 20, 2025.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.33 to $24.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.79 to $25.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.81 to $25.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. F51/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 28, 2024, contingent upon the consummation of the Issuer's initial public offering, and subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Samira ShaikhlyChief People Officer
4Rule 10b5-1 plan disclosed
Filed Mar 4, 2026Period of report Mar 2, 20260001193125-26-092050
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF2F34,090$27.5052$112.50K67,156Direct
SaleMar 2, 2026
Common StockF2F466,363$28.1383$1.87M793Direct
Filing footnotes · 6
  1. F1Includes 793 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on October 31, 2025 in a transaction that was exempt under Rule 16b-3(c).
  2. F2This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 31, 2025.
  3. F3The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.90 to $27.89. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  4. F4The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.90 to $28.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  5. F525% of the shares underlying this option vested on February 1, 2024, with the remainder vesting in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service the Issuer on each such vesting date.
  6. F61/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR
Elizabeth BhattPresident and COO
4Rule 10b5-1 plan disclosed
Filed Feb 20, 2026Period of report Feb 18, 20260001193125-26-061675
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 18, 2026
Common StockF1F22,200$28.4594$62.61K176,009Direct
SaleFeb 18, 2026
Common StockF1F31,800$29.5831$53.25K174,209Direct
Filing footnotes · 4
  1. F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on October 20, 2025.
  2. F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.09 to $29.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.12 to $29.98. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F41/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 28, 2024, contingent upon the consummation of the Issuer's initial public offering, and subject to the Reporting Person's continuous service to the Issuer on each such date.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.